Anixa Biosciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Anixa Biosciences, Inc. (ANIX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Oct 2024Oct 2023Oct 2022Oct 2021Oct 2020Oct 2019Oct 2018
Operating Activities
Net Income-11.03-12.55-9.81-13.60-12.95-10.02-11.82-14.24
Depreciation & Amortization-0.110.040.050.040.060.090.470.34
Stock Based Compensation3.684.424.426.008.064.140.000.00
Change in Working Capital0.150.53-1.060.490.08-0.460.480.07
Change in Accounts Receivable0.170.10-0.22-0.030.000.060.000.00
Change in Accounts Payable-0.360.32-0.060.13-0.10-0.350.000.00
Change in Other Working Capital0.340.380.310.750.17-0.170.000.00
Other Operating Activities0.130.380.310.75-0.17-0.076.130.00
Net Cash from Operating Activities-7.17-7.34-6.21-6.49-4.94-6.18-4.74-4.27
Investing Activities
Capital Expenditures0.000.000.000.000.00-0.020.18-0.04
Purchases of Investments-44.36-63.77-44.41-22.49-3.96-0.290.000.00
Sales/Maturities of Investments49.2368.0538.8111.7612.54-0.29-0.351.50
Net Cash from Investing Activities4.874.28-5.60-10.73-3.92-0.31-0.531.46
Financing Activities
Common Stock Issued2.282.960.370.4531.579.415.572.47
Common Stock Repurchased0.00-0.010.000.000.000.000.000.00
Other Financing Activities0.000.000.000.000.000.000.010.00
Net Cash from Financing Activities2.283.420.370.4531.579.415.702.53
Summary
Net Change in Cash-0.030.36-11.45-16.7722.712.930.44-0.28
Cash at Beginning of Period1.270.9212.3629.136.423.493.063.34
Cash at End of Period1.241.270.9212.3629.136.423.493.06
Free Cash Flow-7.17-7.34-6.21-6.49-4.94-6.19-4.92-4.31
Supplemental Disclosures
Interest Paid0.000.000.000.000.000.040.060.00